NASDAQ:MLNT Melinta Therapeutics (MLNT) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free MLNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.35▼$0.5052-Week Range N/AVolumeN/AAverage Volume713,628 shsMarket Capitalization$6.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Melinta Therapeutics alerts: Email Address Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. About Melinta Therapeutics Stock (NASDAQ:MLNT)Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.Read More Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. MLNT Stock News HeadlinesApril 23, 2024 | seekingalpha.comSWTX SpringWorks Therapeutics, Inc.February 28, 2024 | msn.comFDA Requests Additional Data for Venatorx and Melinta's Antibiotic CombinationMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.February 27, 2024 | msn.comPromising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIsFebruary 23, 2024 | finance.yahoo.comVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-TaniborbactamDecember 5, 2023 | msn.comCidara, Melinta announce publication of Rezzayo data in medical journalNovember 9, 2023 | finance.yahoo.comMelinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.October 11, 2023 | finance.yahoo.comMelinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023May 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.October 2, 2023 | uk.finance.yahoo.comMelinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)September 26, 2023 | thestreet.comMelinta Therapeutics, Inc.May 15, 2023 | finance.yahoo.comMelinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in CanadaMarch 1, 2023 | seekingalpha.comCidara Therapeutics Sheds Skin, Shifts To ImmunotherapyFebruary 24, 2023 | finance.yahoo.comBiVictriX Therapeutics reports "really exciting" BCX001 dataOctober 20, 2022 | technews.tmcnet.comOptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired EventJuly 27, 2022 | finance.yahoo.comMelinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.October 25, 2021 | finance.yahoo.comMelinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug DevelopmentSeptember 20, 2021 | apnews.comMelinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)See More Headlines Receive MLNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2019Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MLNT CUSIP15130J10 CIK1461993 Webwww.melinta.com Phone908-617-1309FaxN/AEmployees290Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-157,190,000.00 Net Margins-393.39% Pretax MarginN/A Return on Equity-101.29% Return on Assets-28.68% Debt Debt-to-Equity Ratio1.11 Current Ratio1.03 Quick Ratio0.72 Sales & Book Value Annual Sales$96.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$16.96 per share Price / BookN/AMiscellaneous Outstanding Shares13,750,000Free FloatN/AMarket Cap$6.88 million OptionableOptionable Beta4.16 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Erin M. Duffy (Age 51)Chief Scientific Officer & Exec. VP Mr. John H. Johnson (Age 61)CEO & Director Dr. Thomas A. SteitzCo-FounderDr. Peter B. Moore Ph.D.Co-FounderDr. William L. JorgensenCo-FounderKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXTFF PharmaceuticalsNASDAQ:TFFPAdial PharmaceuticalsNASDAQ:ADILEnveric BiosciencesNASDAQ:ENVBShuttle PharmaceuticalsNASDAQ:SHPHView All Competitors MLNT Stock Analysis - Frequently Asked Questions How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics Inc (NASDAQ:MLNT) announced its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share for the quarter, missing the consensus estimate of ($2.55) by $13.12. The biotechnology company had revenue of $15.87 million for the quarter, compared to analysts' expectations of $15.51 million. Melinta Therapeutics had a negative trailing twelve-month return on equity of 101.29% and a negative net margin of 393.39%. When did Melinta Therapeutics' stock split? Shares of Melinta Therapeutics reverse split on the morning of Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Melinta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Novavax (NVAX) and Nabriva Therapeutics (NBRV). This page (NASDAQ:MLNT) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
